stockrowRevolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
Follow RVMD
Alert me
Revolution Medicines, Inc. (RVMD) Shares outstanding
Revolution Medicines, Inc.'s shares outstanding at the end of fiscal 2025 was $190.1M, up 13.3% from $167.7M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $214.9M. Over the past ten years it has ranged from $1.7M (fiscal 2017) to $190.1M (fiscal 2025) — the current reading is the highest in ten years. Revolution Medicines, Inc. ranks 41st of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $190.1M | 13.35% |
| FY2024 | $167.7M | 48.24% |
| FY2023 | $113.2M | 40.34% |
| FY2022 | $80.6M | 10.74% |
| FY2021 | $72.8M | 32.68% |
| FY2020 | $54.9M | 1,878.87% |
| FY2019 | $2.8M | 20.62% |
| FY2018 | $2.3M | 33.43% |
| FY2017 | $1.7M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $214.9M | 1.92% |
| Jun 2026 | $210.9M | 6.46% |
| Mar 2026 | $198.1M | 4.19% |
| Dec 2025 | $190.1M | 0.47% |
| 27 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ROIV Roivant Sciences Ltd. compare | $720.8M |
| GMAB Genmab A/S Sponsored ADR compare | $617.1M |
| RPRX Royalty Pharma PLC compare | $557.0M |
| BNTX BioNTech SE Sponsored ADR compare | $252.7M |
| INSM Insmed, Inc. compare | $218.8M |
| RVMD Revolution Medicines, Inc. | $214.9M |
| INCY Incyte Corporation compare | $203.2M |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $115.8M |
| ARGX argenex SE compare | $64.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on RVMD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement